They include those seeking to further cut payments to drug companies for sales made to the Medicare outpatient drug program (Part D), a program which has extended access to affordable medicines for millions of patients while keeping costs under control.
FORBES: Merck CEO: Health Care Beyond the Fiscal Cliff Requires Structural Changes